JOHNSON & JOHNSON is 14.9x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($574.10 B vs $38.52 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ALNY | JNJ |
|---|---|---|
| Market cap | $38.52 B | $574.10 B |
| US-listed rank | #396 | #20 |
| Revenue (latest FY) | $3.71B | $94.19B |
| Net income (latest FY) | $313.75M | $26.80B |
| Net margin | 8.4% | 28.5% |
| P/E (trailing FY) | 122.8 | 21.4 |
| SEC filings | 1,651 | 984 |
JOHNSON & JOHNSON is 14.9x more valuable than ALNYLAM PHARMACEUTICALS, INC. by market capitalization ($574.10 B vs $38.52 B).
In their latest fiscal years, ALNYLAM PHARMACEUTICALS, INC. reported $3.71B in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: ALNYLAM PHARMACEUTICALS, INC. and JOHNSON & JOHNSON, or browse the full rankings.